USS Investment Management Ltd Has $3.74 Million Stock Position in Quest Diagnostics Incorporated $DGX

USS Investment Management Ltd raised its position in Quest Diagnostics Incorporated (NYSE:DGX) by 18.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,068 shares of the medical research company’s stock after purchasing an additional 2,971 shares during the quarter. USS Investment Management Ltd’s holdings in Quest Diagnostics were worth $3,737,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Key Financial Inc lifted its holdings in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after buying an additional 121 shares during the last quarter. Quattro Advisors LLC acquired a new position in Quest Diagnostics in the fourth quarter worth approximately $25,000. JFS Wealth Advisors LLC increased its holdings in Quest Diagnostics by 114.3% in the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after buying an additional 80 shares during the last quarter. Harbor Investment Advisory LLC raised its position in Quest Diagnostics by 113.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 83 shares in the last quarter. Finally, DV Equities LLC bought a new position in Quest Diagnostics during the fourth quarter valued at approximately $27,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Quest Diagnostics

In related news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DGX. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. UBS Group raised their price target on shares of Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Weiss Ratings lowered shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (b)” rating in a research note on Wednesday, June 24th. Barclays upped their price objective on shares of Quest Diagnostics from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Wednesday, April 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $225.00 target price on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.58.

Quest Diagnostics Stock Down 0.2%

DGX opened at $215.35 on Friday. The firm has a market cap of $23.84 billion, a P/E ratio of 23.80, a price-to-earnings-growth ratio of 2.57 and a beta of 0.58. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. The business has a 50 day moving average price of $197.41 and a 200 day moving average price of $193.95. Quest Diagnostics Incorporated has a twelve month low of $164.65 and a twelve month high of $217.41.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter last year, the company posted $1.94 earnings per share. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Research analysts forecast that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th will be paid a $0.86 dividend. The ex-dividend date is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.6%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 38.01%.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.